ORGS - オ―ジェネシス (Orgenesis Inc.)

ORGSのニュース

   Volume - Orgenesis Inc. Short Interest Up 52.4% in May  2022/06/14 21:41:09 Business Mag
Orgenesis Inc. saw a significant increase in short interest in May. As of May 31st, there was short interest totalling 215,400 shares, an increase of 52.4% from the May 15th…
   Oncolytic Virus Cancer Therapy Pipeline Shows Rapid Progress in Clinical Trials, Assesses DelveInsight  2022/05/18 17:00:00 Benzinga
New York, USA, May 18, 2022 (GLOBE NEWSWIRE) -- Oncolytic Virus Cancer Therapy Pipeline Shows Rapid Progress in Clinical Trials, Assesses DelveInsight Oncolytic Virus Cancer Therapy Pipeline involves 70+ key companies continuously working towards developing 100+ Oncolytic Virus Cancer therapies, as per DelveInsight DelveInsight''s '' Oncolytic Virus Cancer Therapy Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Oncolytic Virus Cancer Therapy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Oncolytic Virus Cancer Therapy pipeline domain. Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report DelveInsight''s Oncolytic Virus Cancer Therapy Pipeline report depicts a robust space with 70+ active players working to develop 100+ pipeline therapies for Oncolytic Viruses Cancer treatment. Leading Oncolytic Virus Cancer Therapy companies such as Lokon Pharma, Merck, Wuhan Binhui Biotechnology, CG Oncology, Oncolys Biopharma, Replimune, Transgene, Sorrento Therapeutics, ORCA Therapeutics, TILT Biotherapeutics, BioEclipse Therapeutics, Oncolytics Biotech, Oncorus, DNAtrix, OncoMyx Therapeutics, Vyriad, Boehringer Ingelheim, IconOVir Bio, Imugene, Turnstone Biologics, Immvira Pharma, SillaJen Biotherapeutics, Advantagene, Nouscom, TOT Biopharm, Elicera Therapeutics, Takeda, Candel Therapeutics, Valo Therapeutics, Tessa Therapeutics, PsiOxus Therapeutics, KaliVir Immunotherapeutics, Oncos Therapeutics, Mustang Bio, Takara Bio, Vaxiion Therapeutics, Synthetic Biologics, Calidi Biotherapeutics, Genelux Corporation, Shanghai Sunway Biotech, BioInvent International AB, Guizhou Sinorda Biomedicine, EpicentRx, Hookipa Pharma Inc.
   Orgenesis to raise $14.8M in stock and warrants offering  2022/03/31 12:04:54 Seeking Alpha
Orgenesis (ORGS) entered into a definitive securities purchase agreement with certain investors for the sale of 4.9M shares in a private placement at $3/share and warrants to purchase up…
   Orgenesis'' (ORGS) CEO Vered Caplan on Q4 2021 Results - Earnings Call Transcript  2022/03/31 02:50:23 Seeking Alpha
   Orgenesis GAAP EPS of -$0.74, revenue of $35.5M  2022/03/30 11:22:02 Seeking Alpha
Orgenesis press release (ORGS): FY GAAP EPS of -$0.74.Revenue of $35.5M (+361.0% Y/Y).
   Orgenesis to raise $14.8M in stock and warrants offering  2022/03/31 12:04:54 Seeking Alpha
Orgenesis (ORGS) entered into a definitive securities purchase agreement with certain investors for the sale of 4.9M shares in a private placement at $3/share and warrants to purchase up…
   Orgenesis'' (ORGS) CEO Vered Caplan on Q4 2021 Results - Earnings Call Transcript  2022/03/31 02:50:23 Seeking Alpha
   Orgenesis GAAP EPS of -$0.74, revenue of $35.5M  2022/03/30 11:22:02 Seeking Alpha
Orgenesis press release (ORGS): FY GAAP EPS of -$0.74.Revenue of $35.5M (+361.0% Y/Y).
   Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update  2022/03/30 11:00:00 GlobeNewswire
Orgenesis to host conference call today at 12:00 PM ET Orgenesis to host conference call today at 12:00 PM ET
   Orgenesis Inc Shares Fall 1.3% Below Previous 52-Week Low - Market Mover  2022/01/14 03:13:17 Kwhen Finance
Orgenesis Inc (ORGS) shares closed 1.3% lower than its previous 52 week low, giving the company a market cap of $59M. The stock is currently down 14.9% year-to-date, down 52.7% over the past 12 months, and up 390.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 33.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -693.7% The company's stock price performance over the past 12 months lags the peer average by 250.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Orgenesis Inc Shares Fall 1.3% Below Previous 52-Week Low - Market Mover  2022/01/14 03:13:17 Kwhen Finance
Orgenesis Inc (ORGS) shares closed 1.3% lower than its previous 52 week low, giving the company a market cap of $59M. The stock is currently down 14.9% year-to-date, down 52.7% over the past 12 months, and up 390.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 33.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -693.7% The company's stock price performance over the past 12 months lags the peer average by 250.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Orgenesis Inc Shares Close in on 52-Week Low - Market Mover  2022/01/08 14:06:48 Kwhen Finance
Orgenesis Inc (ORGS) shares closed today at 1.6% above its 52 week low of $2.55, giving the company a market cap of $62M. The stock is currently down 10.1% year-to-date, down 47.0% over the past 12 months, and up 418.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 8.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.9% lower than its 5-day moving average, 10.8% lower than its 20-day moving average, and 37.0% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -644.3% The company's stock price performance over the past 12 months lags the peer average by 230.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Orgenesis (NASDAQ:ORGS) versus Stealth BioTherapeutics (NASDAQ:MITO) Head to Head Comparison  2021/12/23 02:16:42 Dakota Financial News
Orgenesis (NASDAQ:ORGS) and Stealth BioTherapeutics (NASDAQ:MITO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Analyst Ratings This is a summary of current ratings for Orgenesis and Stealth BioTherapeutics, as provided []
   Orgenesis Inc. (NASDAQ:ORGS) Stock Position Raised by Millennium Management LLC  2021/12/14 09:14:45 Dakota Financial News
Millennium Management LLC lifted its stake in shares of Orgenesis Inc. (NASDAQ:ORGS) by 954.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 131,790 shares of the company’s stock after acquiring an additional 119,296 shares during the quarter. Millennium Management […]
   Orgenesis-Theracell Joint Venture Secures 32M Grant From Greek Government  2021/11/29 17:47:00 Benzinga
Orgenesis Inc (NASDAQ: ORGS ) announced that its joint venture with Theracell Advanced Biotechnology S.A. in Greece has been designated a "Priority Investment of Strategic National Importance." The designation was awarded by Enterprise Greece, the official Greek national investment and trade promotion agency responsible for allocating the government funds. The joint venture will be inducted into Greece''s fast-track licensing and approval process. In addition, the joint venture will also receive Full story available on Benzinga.com

calendar